Europe Bladder Cancer Therapeutics and Diagnostics Market Size (2024 - 2029)

Europe Bladder Cancer Therapeutics And Diagnostics Market Analysis

Europe's bladder cancer therapeutics and diagnostics market is projected to register a CAGR of 5% over the forecast period.

• The COVID-19 pandemic significantly impacted the Europe bladder cancer therapeutics and diagnostics market. For instance, according to the study published by IOS Press, in June 2022, the share of bladder cancer diagnoses fell by 14% during the first COVID wave in the Netherlands. Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics was significantly impacted.
• However, the sector has been recovering since restrictions were lifted, resulting in the return of the normal pre-pandemic demand levels for therapeutic and diagnostic procedures. Thus, the Europe bladder cancer therapeutics and diagnostics market is expected to grow over the forecast period.
• Factors driving the market growth include increasing awareness of bladder diseases and available therapies, increasing the burden of bladder cancer, and innovations in drug development. For instance, according to an article published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, bladder cancer is one of Europe's top 5 most common cancers, claiming more than 67,000 lives every year.
• Furthermore, in May 2022, Bladder Cancer Awareness Month (BCAM) was recognized by EFPIA, providing an important opportunity for the bladder cancer community to come together and shine a spotlight. As per the event, around 151,000 Europeans are diagnosed with bladder cancer yearly, making it the fifth most frequent cancer diagnosis on the continent and the second most common urological cancer. Hence, with the growing burden of bladder cancer, the demand for its diagnosis and treatment is expected to increase, thereby boosting the market growth.
• Additionally, various strategies adopted by the key market players, such as product launches and mergers and acquisitions, are anticipated to increase the demand for bladder cancer therapeutics and diagnostics, thereby driving market growth over the forecast period.
• For instance, in April 2022, Astellas Pharma Inc. and Seagen Inc. received the European Commission (EC) approval for PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.
• Therefore, the factors mentioned above, such as increasing awareness of bladder diseases and available therapies, increasing burden of bladder cancer, and innovations in drug development, are attributed collectively to the studied market growth over the forecast period. However, the rise in patent expirations is the primary factor restraining the market's growth.

Europe Bladder Cancer Therapeutics And Diagnostics Industry Segmentation

As per the scope of the report, bladder cancer arises from the epithelial lining of the urinary bladder. It is the ninth most common cancer worldwide, with the highest recurrence rate of any malignancy. Over the past ten years, bladder cancer has gradually developed, with a massive void of unmet needs. 

The Europe bladder cancer therapeutics and diagnostics market is segmented by product (therapeutics (chemotherapy, immunotherapy, and other therapeutics), and diagnostics (cystoscopy, bladder ultrasound, urinalysis, and other diagnostics)), cancer type (transitional cell bladder cancer, squamous cell bladder cancer, and other cancer types), and geography (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe). 

The report offers the value (in USD million) for the above segments.